Frontlight ResearchEarly access
TerminatedNo phase
Wearable Auscultation Device Validation in Children
Key facts
- Who runs it
- Strados Labs, Inc.
- Where
- Chicago, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 36 people enrolled
- Started
- 7 Aug 2023
- Ended
- 24 Jun 2024
- Type of study
- Observational, 2 groups
- Treatments tested
- RESP™ Biosensor
- Record updated
- 5 July 2024
- Why it stopped
- The Principal Investigator is departing from the study site.
Who can take part
- Age
- 4 years to 17 years
- Sex
- Women and men
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Any child aged 4-17 years of age
- Admitted to Lurie Children's Hospital or the Emergency Department at Lurie
- Normal breath sounds cohort: (16 patients ages 4-10, 16 patients ages 11-17); Admitted for a non-respiratory complaint; Normal breath sounds on screening examination
- Wheeze cohort: (53 patients ages 4-10, 53 patients ages 11-17); Admitted for pathologic process that may lead to wheezing (e.g., asthma); Presence of wheeze on screening examination
Who cannot take part
- Unstable disease posing a threat to life
- Adhesive allergy
- Children less than age 4, adults (age 18 and above)
- Patients in the ambulatory setting
- Unable to provide consent
- Intubated patients
Where in United States
- Lurie Children's Hospital of ChicagoChicago, United States
About the trial
What the trial wants to find out
This observational clinical study is an evaluation of a diagnostic tool through comparison. Similar to a validation study, the output of the RESP device will be compared to physician auscultation, surrogated by having an attending pulmonologist listen to blinded recordings.
The 2 groups in the trial
- Normal Breath Sound Cohort
32 patients ages 4-10, 16 patients ages 11-17) * Admitted for a non-respiratory complaint * Normal breath sounds on screening examination
Treatment: RESP™ Biosensor
- Wheeze Cohort
(106 patients ages 4-10, 53 patients ages 11-17) * Admitted for pathologic process that may lead to wheezing (e.g., asthma) * Presence of wheeze on screening examination
Treatment: RESP™ Biosensor
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 5 July 2024